Bibliographic citations
Luna, L., (2022). Dosis de vancomicina y niveles terapéuticos en los pacientes menores de 18 años del Instituto Nacional de Salud del Niño San Borja durante el periodo diciembre del 2015 a abril del 2019 [Universidad Peruana Cayetano Heredia]. https://hdl.handle.net/20.500.12866/11936
Luna, L., Dosis de vancomicina y niveles terapéuticos en los pacientes menores de 18 años del Instituto Nacional de Salud del Niño San Borja durante el periodo diciembre del 2015 a abril del 2019 []. PE: Universidad Peruana Cayetano Heredia; 2022. https://hdl.handle.net/20.500.12866/11936
@mastersthesis{renati/685636,
title = "Dosis de vancomicina y niveles terapéuticos en los pacientes menores de 18 años del Instituto Nacional de Salud del Niño San Borja durante el periodo diciembre del 2015 a abril del 2019",
author = "Luna Vilchez, Luzgarda Medalit",
publisher = "Universidad Peruana Cayetano Heredia",
year = "2022"
}
Objective: To determine if there is an association between doses and trough vancomycin levels in pediatric patients. Methods: Retrospective cohort study. Hospitalized patients from 29 days to 18 years were included. Data were collected from electronic and medical records. Vancomycin doses were measured in mg/kg/day and categorized into 3 groups (<40, 40-60, and >60). Trough levels corresponded to serum vancomycin concentrations in μg/mL, taken 30 minutes prior to the fourth dose. This variable was categorized into 3 groups: sub-therapeutic (<10), therapeutic (10-15) and supra-therapeutic (>15). The association between doses and trough vancomycin levels was evaluated using a multinomial logistic regression model, taking the therapeutic level as the reference category. Unadjusted and confounder-adjusted relative risk ratios (RRR) were calculated. Results: 390 patients were evaluated, 55.1% were male and 45.1% were infants. Regarding the vancomycin trough levels, 52.8% of the patients obtained sub-therapeutic levels, 16.9% therapeutic levels, and 30.3% supra-therapeutic levels. In the prescription doses, 25.6% of patients received doses <40 mg/kg/day, 58.5% doses of 40-60 mg/kg/day, and 15.9% doses >60 mg/kg/day. The adjusted RRR showed that patients who received vancomycin doses <40 mg/kg/day (vs. 40-60 mg/kg/day) were less likely to obtain supra-therapeutic levels than to obtain therapeutic levels (RRR: 0.3, 95%CI: 0.1-0.8, p=0.018). The other comparisons between vancomycin doses and trough levels were not statistically significant. Conclusions: Lower vancomycin doses were less likely to obtain supra-therapeutic levels in pediatric patients.
This item is licensed under a Creative Commons License